www.fdanews.com/articles/84768-antares-to-continue-anturol-gel-studies
ANTARES TO CONTINUE ANTUROL GEL STUDIES
February 22, 2006
Antares expects to begin a late-stage clinical trial this year for its gel-based topical overactive bladder treatment following favorable mid-stage results. The company plans to start a Phase III trial for its Anturol gel in the second half of the year.
In a Phase II trial, Anturol was compared with a patch containing oxybutynin, also the active ingredient in Anturol. In the study, 98 percent of those using the topical gel did not report skin irritation, compared with a skin irritation rate of 50 percent for the patch.